Correlation Between Vaspin Gene Polymorphism and Serum Vaspin Levels in Psoriasis Vulgaris

NCT07320872 | Recruiting DMC

• 1 other identifier: Psoriasis Vulgaris Vaspin Gene
• Study Type: observational
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

Psoriasis is a common immune-mediated inflammatory skin disease affecting at least 100 million individuals worldwide. In Egypt, the prevalence of psoriasis ranges between 0.19% and 3% of the Egyptian people. It is associated with poor quality of life, reduced life expectancy and multimorbidity including psoriatic arthritis, obesity and cardiovascular disease. Vaspin (VASP, SERPIN 12) is a recently discovered adipokine that has been isolated from the visceral adipose tissue of a rat model of type 2 diabetes. It is coded by the gene SERPNA12 located on the long arm of chromosome 14q32.13 and consists of six exons and five introns.

Conditions

Psoriasis Vulgaris

Outcome Measures

Primary Outcomes (1)

• Detection of vaspin gene polymorphism

  Assessment of vaspin gene polymorphism in psoriasis patients to determine the disease severity

  12 Months

Study Arms (2)

Group A: Psoriasis Patients

About 30 patients suffering from Psoriasis Vulgaris will subject to vaspin gene polymorphism measure and Assessment of the disease severity will be performed by using Psoriasis area and severity index score (PASI score) for all patients.

Biological: vaspin gene polymorphism

Group B: Control Group

About 30 healthy participants will share as A control Group

Biological: vaspin gene polymorphism

Interventions

vaspin gene polymorphism BIOLOGICAL

to detect the correlation between vaspin gene polymorphism and serum vaspin levels among psoriasis patients. * To detect the relationship between the risk of psoriasis and the vaspin gene polymorphism. * To detect correlation between vaspin gene polymorphism and the severity of psoriasis.

Also known as: Serum Vaspin Levels

Group A: Psoriasis Patients; Group B: Control Group

Eligibility Criteria

• Age: 18 Years - 50 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)
• Sampling Method: Non-Probability Sample

Study Population

The study will include (30) psoriasis patients and (30) normal control. and will be conducted on psoriasis patients and the healthy persons whom will be selected from the outpatient clinic of the Dermatology, Venereology, and Andrology Department, at Aswan University Hospital.

You may qualify if:

• Newly diagnosed cases or stopped treatment of at least 6 months of psoriasis patients.
• Pateints with any age and gender.

You may not qualify if:

• Pregnancy and lactation.
• Patients with chronic diseases: cardiac diseases, hepatic disorders, chronic renal failure or malignancies.
• Patients with associated inflammatory disease such as infections and autoimmune diseases.

Sponsors & Collaborators

• Aswan University: lead

Study Sites (1)

Aswan University Hospital

Aswān, Egypt

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

Blood sampling withdrawn from both healthy and control groups subjected for DNA extraction and SNP genotyping of vaspin gene polymorphism by real time - PCR. and Serum samples will be also taken to detect the serum level of vaspin concentrations by ELISA.

Study Officials

• Moustafa Adam Ali El Taieb, Professor

  Dermatology, Venereology and Andrology.Faculty of Medicine, Aswan University

  STUDY CHAIR

• Hoda Soltan Sherkawy El Bakry, Lecturer

  Medical biochemistry,Faculty of Medicine,Aswan University

  STUDY DIRECTOR

Central Study Contacts

Ola Mahmoud Samy Mohamed, MSC

CONTACT

+201025592922; olaelqousy@gmail.com

Mahmoud Ahmed Ali, Lecturer

CONTACT

+201002364902; dr.mahmoudali@aswu.edu.eg

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Specialist at Dermatology, Venereology and Andrology Department

Study Record Dates

• First Submitted: December 21, 2025
• First Posted: January 6, 2026
• Study Start: August 10, 2025
• Primary Completion (Estimated): August 10, 2026
• Study Completion (Estimated): August 20, 2026
• Last Updated: January 6, 2026

Record last verified: 2025-08

Locations

EG (1)